Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-644.76	-463.66	-328.07	-239.48	-186.48
Depreciation & Amortization	83.7	36.49	24.4	11.76	8.41
Stock-Based Compensation	111.22	81.69	53.5	27.91	14.84
Other Adjustments	64.34	33.06	6.64	11.37	4.92
Changes in Accounts Payable	-2.62	6.44	-0.99	1.77	1.75
Changes in Accrued Expenses	-9.74	5.26	9.42	-0.05	13.33
Changes in Unearned Revenue	-36.77	-28.04	-41.08	110.32	-10
Changes in Other Operating Activities	62.81	-30.41	-11.62	-7.11	-5.38
Operating Cash Flow	-371.81	-359.17	-287.78	-83.52	-158.61
Capital Expenditures	-6.47	-13.7	-11.96	-37.06	-39.8
Purchases of Intangible Assets	-2.16	-3.35	-0.6	-0.3	-
Purchases of Investments	-3.81	-	-	-	-301.14
Proceeds from Sale of Investments	-	-	0.48	230.61	69.19
Other Investing Activities	-4.44	277.1	1.84	-	-
Investing Cash Flow	-16.87	260.06	-10.23	193.25	-271.74
Long-Term Debt Repaid	-8.43	-4.44	-0.77	-0.09	-12.8
Net Long-Term Debt Issued (Repaid)	-8.43	-4.44	-0.77	-0.09	-12.8
Issuance of Common Stock	532.96	308.56	140.9	154.44	471.34
Net Common Stock Issued (Repurchased)	532.96	308.56	140.9	154.44	471.34
Other Financing Activities	-3	-	-	-	-
Financing Cash Flow	521.53	304.12	140.13	154.35	458.54
Effect of Exchange Rate Changes on Cash and Cash Equivalents	18.04	-3.41	0.19	-0.31	-
Net Cash Flow	150.9	201.6	-157.69	263.76	28.18
Free Cash Flow	-378.28	-372.87	-299.74	-120.58	-198.41
FCF Margin	-506.52%	-633.71%	-672.43%	-302.65%	-1949.42%
Free Cash Flow Per Share	-0.85	-1.36	-1.44	-0.69	-1.58
Levered Free Cash Flow	-562.26	-492.06	-360.64	-159.95	-230.98
Unlevered Free Cash Flow	-557.08	-501.8	-377.59	-166.11	-214.47

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q